QPS acquires Bio-Kinetic Clinical Applications

Bio-Kinetic, an early clinical research organization with a 240-bed phase I facility, will retain its name and become a wholly-owned subsidiary of QPS Holdings.

QPS and Bio-Kinetic’s collective services cover bioanalysis, preclinical DMPK, biomarkers, gene expression, pharmacogenomics markers, and Phase I studies supporting development of generic products and clinical development of NMEs. With the completion of this acquisition the pharmaceutical and biotechnology industries will now have access to dedicated, focused scientific expertise in the drug development spectrum from discovery and preclinical through IND into Phase I research.